对比研究胎儿和成年来源的胰岛前体细胞体外增殖和分化潜能

Comparative Study on the Proliferation and Differentiation of Fetal and Adult Human Islet-derived Precursor Cells in vitro

对比研究胎儿和成年胰岛来源的前体细胞(hIPCs)体外增殖和分化,探讨胎儿和成年hIPCs的体外增殖和分化潜能,为细胞移植治疗糖尿病提供实验数据。体外分离培养胎儿和成体hIPCs,诱导分化,通过免疫组织化学、分子生物学方法,检测hIPCs体外增殖潜能和分化效率。与成年hIPCs相比较,胎儿hIPCs在体外具有更强的增殖潜能,BrdU掺入率明显高于成年胰岛来源的hIPCs(P<0.05)。体外诱导hIPCs分化成具有分泌胰岛素功能的胰岛样细胞团(ICCs),免疫荧光染色显示ICCs表达Insulin、Glucagon和Somatostatin,定量检测Insulin、PDX-1和ISL-1基因的相对表达量,胎儿来源的ICCs明显高于成年ICCs(P<0.05),分别是成年ICCs的1.69倍、1.51倍和1.81倍。提示胎儿来源的胰岛前体细胞具有较强的增殖和分化能力。

Hyperglycemia arises from the selective destruction of pancreatic insulin producing β-cells in type 1 and the late stages of type 2 diabetes. Cell therapy represents a potential cure for diabetes mellitus, but is limited by availability of human pancreatic tissue. Stem/progenitors cells within pancreatic tissue are a potential source for transplantation because they can expand exponentially and produce functional insulin-producing cells. Human islet-derived precursor cells （hlPCs） are capable to proliferate and differentiate into functional cells that secreted insulin in response to glucose in vivo and in vitro. In this study, we isolated and cultured hlPCs from fetal and adult human islets, and compared the proliferation and differentiation ability of hlPCs in vitro. Results showed that fetal hlPCs had greater potentiality for proliferation and differentiation than that of adult hlPCs. Our finding suggested that fetal hlPCs might be more suitable for clinical and experimental study on cell transplantation for diabetes.